Accueil / Communiqués / InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Monday, January 14th 2019 at 1:00pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and
clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries (SCIs), today announces the
appointment of Richard Christopher as its Chief Financial Officer and
Treasurer, effective January 14, 2019.

Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer
of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and
solutions for the early identification and treatment of cancer. Prior to
iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief
Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical
technology company focused on cancer detection imaging solutions, with
primary applications in dermatology. Prior to Caliber, Mr. Christopher
held various positions of increasing responsibility at DUSA
Pharmaceuticals, Inc., a Nasdaq-listed dermatology company focused on
the treatment of precancerous skin lesions, where he ultimately served
as Chief Financial Officer through its acquisition and integration into
Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds a Master of
Science in Accounting from Suffolk University and a Bachelor of Science
in Finance from Bentley University.

Richard Toselli, M.D., InVivo’s President and Chief Executive Officer
said, “Rich’s more than 25 years of invaluable financial experience,
including at various publicly traded life science companies, make him a
key asset in the navigation of InVivo’s goals. He has a proven track
record in diverse financial management, financing transactions and
strategic planning, and most significantly, Rich shares a passion for
bringing treatments and therapies to patients in areas of unmet need. On
behalf of the Board and Management, we welcome Rich to the InVivo team.”

“It is an exciting time to join InVivo, especially during a
transformative and pivotal stage in the company’s development. I look
forward to working with the InVivo Board of Directors and Management
Team to drive its mission of helping this underserved patient population
and bringing value to shareholders,” stated Mr. Christopher.

Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

In connection with the appointment of Mr. Christopher and in accordance
with the terms of an employment agreement between Mr. Christopher and
the company, the Board granted to Mr. Christopher a stock option to
purchase up to 90,000 shares of InVivo’s common stock, vesting over
three years, with one-third (1/3) of the shares underlying the stock
option vesting on the first anniversary of Mr. Christopher’s start date
with the company, one-third (1/3) vesting on the second anniversary of
Mr. Christopher’s start date, and the remaining one-third (1/3) vesting
on the third anniversary of Mr. Christopher’s start date, subject to Mr.
Christopher’s continued employment by the company on each vesting date.
The vesting of the option is subject to acceleration upon the
termination of Mr. Christopher’s employment by the Company without cause
or by Mr. Christopher for good reason within twelve months following a
change of control. The option was granted effective January 14, 2019 as
an inducement material to Mr. Christopher’s acceptance of employment
with InVivo, in accordance with NASDAQ Listing Rule 5635(c)(4). The
option has an exercise price per share equal to the closing price of a
share of Common Stock on the Nasdaq Capital Market on January 14, 2019.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In January 2018, the company announced
updated clinical evidence, including improvements in patients with acute
spinal cord injury (SCI), from its INSPIRE study of the Neuro-Spinal
Scaffold
™. The publicly traded company is headquartered in
Cambridge, MA.

Contacts

IR:
Bret Shapiro, Managing Partner
CORE IR
Phone:
(516) 222-2560
brets@coreir.com

MEDIA:
Jules Abraham
CORE IR
Phone: (917) 885-7378
julesa@coreir.com

Source: InVivo Therapeutics Holdings Corp.


Voir aussi

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, January 18th 2019 at 9:05pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today …